読み込み中
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
前日終値
$331.61
+$4.31 · +1.32%
日中の時刻はETです。市場データは遅延する場合があります。
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
日中レンジ
現在 $331.61
52週レンジ
現在 $331.61
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
80
割安
センチメント
50
まちまち
リスク
22
中程度のリスク
モメンタム
78
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
日中レンジ
現在 $331.61
52週レンジ
現在 $331.61
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3.89億 USD | 2.91億 USD | 5069.9万 USD | — | — |
| 売上原価 | 2877.3万 USD | 2006.1万 USD | 309.4万 USD | — | — |
| 粗利益 | 3.6億 USD | 2.7億 USD | 4760.5万 USD | — | — |
| 研究開発 | 5804.5万 USD | 5357.3万 USD | 4643.1万 USD | 4246.1万 USD | 2788.4万 USD |
| 販売・一般管理 | 1.47億 USD | 1.14億 USD | 9840.1万 USD | 7773.5万 USD | 4039.1万 USD |
| 営業費用 | 1.99億 USD | 2.05億 USD | 1.57億 USD | 1.45億 USD | 6827.5万 USD |
| 受取利息 | 2817.6万 USD | 2966.1万 USD | 2262.4万 USD | 522.1万 USD | 19.7万 USD |
| 支払利息 | — | — | — | — | 149.2万 USD |
| 減価償却費と償却費 | 655.1万 USD | 671.4万 USD | 500.7万 USD | 405.5万 USD | 276.9万 USD |
| 営業利益 | 1.61億 USD | 6569.5万 USD | −1.1億 USD | −1.45億 USD | −6827.5万 USD |
| 純利益 | 2.05億 USD | 8915.9万 USD | 1093.2万 USD | −1.4億 USD | −6957万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$395.2
上昇余地（19.18%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.2億0.01%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.32億0.12%1853億 USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM2.25億0.29%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1.41億1.43%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK1.33億0.29%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1.1億0.11%954億 USD0.05%$235+0.80%
Invesco S&P MidCap Momentum ETFXMMO8937.78万1.25%71.38億 USD0.34%$148.79+0.96%
iShares Russell 2000 Growth ETFIWO7910.25万0.57%139.17億 USD0.24%$356.78+0.94%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOiShares Russell 2000 Growth ETFIWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
